Compass Pathways CEO says psychedelic therapy company will proceed cautiously before accelerating its growth

Compass Pathways is preparing for regulatory review of its psychedelic therapy later this year, but its CEO says the company intends to proceed cautiously before accelerating. The approach is summarized as “go slow before we go fast,” signaling a measured strategy around development, regulatory milestones, and potential commercialization. The supplied material identifies the company and its planned review but does not specify the therapy's substance, the regulatory agency, the review outcome, financial details, or the timeline for any broader rollout. The item appears in STAT's biotech coverage and is associated with wider concerns about conditions facing biotechnology companies on Wall Street.